通过天眼查大数据分析，浙江大洋生物科技集团股份有限公司共对外投资了15家企业，参与招投标项目 62次，知识产权方面有商标信息15条，专利信息111条，此外企业还拥有行政许可91个。 大洋生物最新一期业绩显示，截至2025一季报，公司营业总收入2.49亿元、同比增长27.78%，归属净利 润2934.32万元，同比增长73.44%，扣非净利润2976.10万元，同比增长88.88%，流动比率1.285、速动比 率1.063、资产负债率34.58%。 天眼查商业履历信息显示，浙江大洋生物科技集团股份有限公司，成立于1976年，位于杭州市，是一家 以从事化学原料和化学制品制造业为主的企业。企业注册资本8400万人民币，实缴资本8400万人民币。 公司法定代表人为陈阳贵。 金融界消息 截至2025年8月13日收盘，大洋生物（003017）报收于33.72元，下跌3.3%，换手率 19.61%，成交量13.59万手，成交金额4.65亿元。 资金流向方面，今日主力资金净流出1104.27万元，占比成交额2.37%。其中，超大单净流出1091.59万 元、占成交额2.35%，大单净流出12.67万元、占成交额0.03%，中 ...

Market Overview - The Shanghai Composite Index rose by 0.5% to 3665.92 points, the Shenzhen Component Index increased by 0.53% to 11351.63 points, the ChiNext Index climbed by 1.24% to 2409.4 points, and the STAR 50 Index gained 1.91% to 1069.81 points. The total trading volume in the Shanghai and Shenzhen markets reached 18815.2 billion yuan [1]. Sector Movements - Market hotspots were scattered, with active performance in the robotics sector, leading to stocks like Feiya and others hitting the daily limit. The brain-machine interface concept also saw strength, with stocks like Zhejiang Dongri reaching the daily limit. The real estate sector was active, with companies like Shahe Co. also hitting the daily limit [1]. Stock Performance - A total of 60 stocks hit the daily limit, with 112 stocks rising over 7%, 82 stocks increasing between 5-7%, and 195 stocks rising between 3-5%. Conversely, 2917 stocks fell within 0-3%, and 15 stocks dropped over 7% [4]. Notable Stocks - Key stocks hitting the daily limit included: - Jiuding Investment (600053.SH) with plans for acquisition and involvement in humanoid robots and real estate [5] - Shahe Co. (000014.SZ) focusing on real estate and project advancement [5] - Zhejiang Dongri (600113.SH) involved in brain-machine interfaces and state-owned enterprise reform [5] - Xinjiang Torch (603080.SH) in the natural gas sector [5] - Feiya (000026.SZ) linked to aerospace and robotics [5] Industry Insights - The Ministry of Industry and Information Technology and six other departments recently released opinions on promoting the innovation and development of the brain-machine interface industry. By 2027, breakthroughs in key technologies are expected, along with the establishment of an advanced technical, industrial, and standard system [6].

证券之星消息，8月12日化学原料板块较上一交易日上涨0.05%，大洋生物领涨。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。化学原料板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 003017 | 大洋生物 | 34.87 | 10.00% | 7.58万 | | 2.58亿 | | 000818 | 航锦科技 | 22.87 | 4.24% | 75.80万 | | 17.15 Z | | 600075 | 新疆天业 | 4.86 | 2.53% | 117.43万 | | 5.62亿 | | 920489 | 佳先股份 | 23.30 | 1.97% | 8.66万 | | 2.04亿 | | 000683 | 博源化工 | 5.90 | 1.72% | 81.28万 | | 4.76亿 | | 663299 | 示盐井神 | 10.98 | 1.48% | 8.35万 | | 9129.13万 | | ...

Market Overview - The Shanghai Composite Index is at 3660.38 points, above the five-day moving average, with a change of 0.35% [1] - The total trading volume of A-shares is 858.514 billion yuan [1] Stocks Breaking the Five-Day Moving Average - A total of 237 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Yutian Guanjia (301173) with a deviation rate of 10.53% and a daily increase of 13.54% [2] - Meiri Hudong (300766) with a deviation rate of 8.80% and a daily increase of 11.81% [2] - Dayang Biological (003017) with a deviation rate of 8.02% and a daily increase of 10.00% [2] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Fenghuo Electronics (000561) with a deviation rate of 7.29% and a daily increase of 9.97% [2] - Shenzhou Taiyue (300002) with a deviation rate of 5.63% and a daily increase of 7.41% [2] - Lain Biological (002166) with a deviation rate of 5.26% and a daily increase of 6.70% [2] Summary of Stocks with Lower Deviation Rates - Stocks with smaller deviation rates that have just crossed the five-day moving average include: - Changchun Gaoxin, Lidasin, and Kaikai Industry [1]

Group 1 - The core issue involves shareholders Yang Xingli and his associates failing to timely notify the company of a 1% increase in their combined shareholding, violating regulations [1][2] - The combined shareholding of Yang Xingli, Yang Mingtai, and Yang Yuetong increased from 5.65% to 6.35% after buying 1.1795 million shares and selling 887,000 shares between February 24, 2025, and July 7, 2025 [1][2] - The stock price of Dayang Bio fluctuated significantly during the trading period, with a minimum price of 17.01 yuan per share and a maximum of 31.9 yuan per share, resulting in a price fluctuation of 69% [2] Group 2 - Dayang Bio's main business includes the production and sale of inorganic salts and veterinary raw materials [3] - The company expects a net profit of 45 million to 55 million yuan for the first half of the year, representing a year-on-year growth of 43.15% to 74.96%, driven by increased production, sales, and prices of potassium carbonate and veterinary raw materials [3] - The Zhejiang Securities Regulatory Bureau has mandated that the shareholders improve their understanding of relevant laws and regulations to prevent future violations [3]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has ordered Yang Xingli, Yang Yueren, and Yang Mingtai of Zhejiang Dayang Biological Technology Group Co., Ltd. to rectify their actions for failing to timely disclose significant events and not fulfilling other responsibilities [1] Summary by Relevant Sections - **Violation Details** - Yang Xingli, after holding 5% of the issued shares of Dayang Biological, along with concerted actors Yang Mingtai and Yang Yueren, traded shares through centralized bidding. They failed to notify the company and announce the fact when their combined holdings increased by 1% [1] - **Regulatory Actions** - The CSRC has imposed corrective measures and recorded the incident in the securities and futures market integrity archives [1]

Group 1 - The company received a decision on August 5 regarding corrective measures against Yang Xingli and his concerted actors for failing to notify the company of their increased shareholding, which violated regulations [1] - Yang Xingli, Yang Mingtai, and Yang Yue Rong collectively increased their shareholding by 1% without timely disclosure, leading to regulatory action from the Zhejiang Regulatory Bureau [1] - The company has communicated the regulatory decision to its shareholders and emphasized the importance of adhering to legal and regulatory requirements for information disclosure [1] Group 2 - The company produces light potassium carbonate, which has characteristics such as low bulk density, large specific surface area, porous structure, and low free alkalinity, making it suitable for high-end applications in food, pharmaceuticals, and pesticides [1] - As a leading enterprise in the domestic potassium carbonate and potassium bicarbonate industry, the company places significant emphasis on technological research and independent innovation [1] - The company has participated in or led the drafting of 8 national/industry standards, covering major products across its main production lines [1]

Group 1 - The company received a decision from the Zhejiang Regulatory Bureau regarding shareholder Yang Xingli and his concerted actions, which mandated corrective measures due to a violation of disclosure regulations [1][2] - Yang Xingli and his associates failed to timely notify the company and announce their shareholding increase of 1% after surpassing the 5% threshold of total issued shares, violating specific articles of the "Measures for the Administration of the Acquisition of Listed Companies" [1][2] - The regulatory decision requires the shareholders to submit a written rectification report within 10 working days and emphasizes the need for improved awareness of stock trading regulations to prevent future violations [2] Group 2 - The company promptly communicated the regulatory decision to relevant shareholders and reminded them to adhere strictly to legal and regulatory requirements for information disclosure [2] - The matter does not involve the company or other shareholders and will not affect the company's normal business operations [2]

关于持股 5%以上股东及其一致行动人权益变动触及 1%整数倍 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江大洋生物科技集团股份有限公司（以下简称"公司"）于近日收到持股 5%以上股东杨兴礼先生及其一致行动人杨月荣、杨明泰（以下合计统称"信息披 露义务人"）的《持股 5%以上股东及其一致行动人权益变动触及 1%整数倍的告知 函》。 证券代码：003017 股票简称：大洋生物 公告编号：2025-070 浙江大洋生物科技集团股份有限公司 | 1.基本情况 | | | | | | | --- | --- | --- | --- | --- | --- | | 信息披露义务人一 | | 杨兴礼 | | | | | 住所 | | 甘肃省兰州市城关区 | | | | | 信息披露义务人二 | | 杨月荣 | | | | | 住所 | | 甘肃省兰州市城关区 | | | | | 信息披露义务人三 | | 杨明泰 | | | | | 住所 | | 甘肃省兰州市城关区 | | | | | 权益变动时间 | | 2025/2/24-2025/7/7 | | | | ...

证券代码：003017 股票简称：大洋生物 公告编号：2025-069 浙江大洋生物科技集团股份有限公司 关于收到浙江监管局对公司股东杨兴礼及其一致行动人采取 责令改正措施的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江大洋生物科技集团股份有限公司（以下简称"公司"）于 2025 年 8 月 5 日收到中国证券监督管理委员会浙江监管局出具的《关于对杨兴礼及其一致行动 人采取责令改正措施的决定》（〔2025〕174 号）（以下简称"决定"）现将相关 内容公告如下： 一、决定的主要内容 "杨兴礼、杨明泰、杨月荣： 近期，杨兴礼在持股达到浙江大洋生物科技集团股份有限公司（以下简称大 洋生物）已发行股份的百分之五以后，一致行动人杨明泰、杨月荣通过集中竞价 方式交易大洋生物股份。你们在合计持股增加百分之一时，未及时将该事实通知 上市公司并公告，违反了《上市公司收购管理办法》（证监会令第 166 号）第十 三条第三款、《上市公司收购管理办法》（证监会令第 227 号）第十三条第三款 的规定。 根据《上市公司收购管理办法》（证监会令第 227 号）第七十五条的规 ...